LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 106

Search options

  1. Book ; Conference proceedings: Idiopathic generalized epilepsies

    Mattson, Richard H.

    [based on presentations ... during the Symposium Uncovering the Mysteries: Idiopathic Generalized Epilepsies, held during the American Epilepsy Society 56th annual meeting in Seattle, Washington ... December 6 - 11, 2002]

    (Epilepsia ; 44, Suppl. 2)

    2003  

    Institution Symposium Uncovering the Mysteries: Idiopathic Generalized Epilepsies
    Author's details guest ed. Richard H. Mattson
    Series title Epilepsia ; 44, Suppl. 2
    Collection
    Language English
    Size 32 S. : Ill., graph. Darst.
    Publisher Blackwell Publ
    Publishing place Malden, MA
    Publishing country United States
    Document type Book ; Conference proceedings
    HBZ-ID HT013702730
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 517 -44,Suppl.2- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Misperceptions on the chance of seizure freedom with antiseizure medications after two failed trials.

    Blond, Benjamin N / Hirsch, Lawrence J / Mattson, Richard H

    Epilepsia

    2020  Volume 61, Issue 8, Page(s) 1789–1790

    MeSH term(s) Anticonvulsants/therapeutic use ; Freedom ; Humans ; Medicine ; Probability ; Seizures/drug therapy
    Chemical Substances Anticonvulsants
    Language English
    Publishing date 2020-07-08
    Publishing country United States
    Document type Letter
    ZDB-ID 216382-2
    ISSN 1528-1167 ; 0013-9580
    ISSN (online) 1528-1167
    ISSN 0013-9580
    DOI 10.1111/epi.16594
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 517: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 475: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book ; Conference proceedings: New antiepileptic drugs

    Mattson, Richard H.

    from discovery to practical use, clinical directions for the future ; an official program of the 21st International Epilepsy Congress September 6, 1995; Sidney, Australia

    (Epilepsia ; 37, Suppl. 6)

    1996  

    Event/congress International Merritt Putnam Symposium (3, 1995, Sydney) ; International Epilepsy Congress (21, 1995, Sydney)
    Author's details Third International Merritt-Putnam Symposium. Guest ed. Richard H. Mattson
    Series title Epilepsia ; 37, Suppl. 6
    Collection
    Keywords Anticonvulsants / pharmacology / congresses ; Anticonvulsants / therapeutic use / congresses ; Antiepileptikum
    Subject Antikonvulsivum ; Anticonvulsivum ; Antiepileptika
    Language English
    Size S55 S.
    Publisher Lippincott-Raven
    Publishing place New York
    Publishing country United States
    Document type Book ; Conference proceedings
    HBZ-ID HT007405855
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 517 -37,Suppl.6- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Book ; Conference proceedings: Managing epilepsy

    Mattson, Richard H.

    the role of gabapentin ; [this symposium was presented at the XVth World Congress of Neurology, held in Vancouver, British Columbia, Canada, on September 6, 1993]

    (Neurology ; 44, Suppl. 5)

    1994  

    Event/congress World Congress of Neurology (15, 1993, VancouverBritishColumbia)
    Author's details Richard H. Mattson, suppl. ed
    Series title Neurology ; 44, Suppl. 5
    Collection
    Keywords Acetic Acids / pharmacology / congresses ; Anticonvulsants / pharmacology / congresses ; Epilepsy / drug therapy / congresses ; Gabapentin ; Epilepsie
    Subject Fallsucht ; CAS 60142-96-3
    Language English
    Size S32 S. : graph. Darst.
    Publisher Advanstar Communications
    Publishing place New York, NY
    Publishing country United States
    Document type Book ; Conference proceedings
    HBZ-ID HT006359209
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Ui II Zs 153 -44,6,Suppl.5- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy.

    Gauthier, Angela C / Mattson, Richard H

    CNS neuroscience & therapeutics

    2015  Volume 21, Issue 7, Page(s) 543–548

    Abstract: Clobazam is an oral 1,5-benzodiazepine used worldwide for the treatment of many types of epilepsies, although it is currently only approved for Lennox-Gastaut syndrome in the USA. This anticonvulsant and anxiolytic therapeutic has repeatedly demonstrated ...

    Abstract Clobazam is an oral 1,5-benzodiazepine used worldwide for the treatment of many types of epilepsies, although it is currently only approved for Lennox-Gastaut syndrome in the USA. This anticonvulsant and anxiolytic therapeutic has repeatedly demonstrated great efficacy and a high safety profile in refractory epilepsy as well as in a few monotherapy trials in both children and adults. Clobazam allosterically activates the GABAA receptor, and it binds less to subunits that mediate sedative effects than other benzodiazepines. It acts quickly, maintaining a therapeutic effect for a long duration due to its active metabolite, N-desmethylclobazam. Dosage is between 5 mg and 40 mg a day, depending on patient weight, efficacy, and tolerability. Efficacy tolerance has not been a problem in the best studies. Clobazam has provided many benefits to epileptic patients. It should be used by clinicians early as an adjuvant therapy in the treatment of refractory epilepsy and even considered as monotherapy in a broad spectrum of epilepsy syndromes.
    MeSH term(s) Anticonvulsants/therapeutic use ; Benzodiazepines/therapeutic use ; Clobazam ; Drug Discovery ; Epilepsy/drug therapy ; Humans
    Chemical Substances Anticonvulsants ; Benzodiazepines (12794-10-4) ; Clobazam (2MRO291B4U)
    Language English
    Publishing date 2015-04-28
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2423467-9
    ISSN 1755-5949 ; 1755-5930
    ISSN (online) 1755-5949
    ISSN 1755-5930
    DOI 10.1111/cns.12399
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Book: The design of clinical studies to assess the efficacy and toxicity of antiepileptic drugs

    Mattson, Richard H.

    (Neurology ; 33, Suppl. 1)

    1983  

    Author's details Richard H. Mattson
    Series title Neurology ; 33, Suppl. 1
    Collection
    Keywords Anticonvulsants ; Clinical Trials ; Research Design
    Language English
    Size 37 S. : graph. Darst.
    Publisher Harcourt Brace Jovanovich Publ
    Publishing place Cleveland, Ohio
    Publishing country United States
    Document type Book
    HBZ-ID HT002911743
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Ui II Zs 153 -33,Suppl.1- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: A novel inherited SCN1A mutation associated with GEFS+ in benign and encephalopathic epilepsy.

    Gauthier, Angela C / Manganas, Louis N / Mattson, Richard H

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

    2017  Volume 40, Page(s) 82–84

    Abstract: Generalized epilepsy with febrile seizures plus (GEFS+) is an autosomal dominant condition often caused by mutations in SCN1A that usually first manifests as childhood simple febrile seizures but may progress to a variety of afebrile generalized seizure ... ...

    Abstract Generalized epilepsy with febrile seizures plus (GEFS+) is an autosomal dominant condition often caused by mutations in SCN1A that usually first manifests as childhood simple febrile seizures but may progress to a variety of afebrile generalized seizure types. Here, we describe the case of an 8-year-old boy with a novel SCN1A mutation who developed febrile seizures at 10months of age which eventually advanced to frequent afebrile tonic-clonic seizures. His condition was unresponsive to several antiepileptic drugs and the ketogenic diet, and he experienced gradual cognitive decline. The patient's father carries the same novel mutation, but he only experienced childhood simple febrile seizures. SCN1A mutations display incomplete penetrance and variable expressivity, and the resulting severity may depend on the location and type of mutation, whether the mutation was spontaneous or inherited, and the effect of modifying alleles. The identification of novel pathogenic SCN1A mutations may eventually advance therapeutic development and prognostic capabilities.
    Language English
    Publishing date 2017-06
    Publishing country Scotland
    Document type Journal Article
    ZDB-ID 1193674-5
    ISSN 1532-2653 ; 0967-5868
    ISSN (online) 1532-2653
    ISSN 0967-5868
    DOI 10.1016/j.jocn.2017.02.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3999: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures.

    Galiana, Graciana L / Gauthier, Angela C / Mattson, Richard H

    Drugs in R&D

    2017  Volume 17, Issue 3, Page(s) 329–339

    Abstract: Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine carboxamide family that is currently approved as adjunctive therapy and monotherapy for partial-onset (focal) seizures. The drug enhances slow inactivation of voltage- ... ...

    Abstract Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine carboxamide family that is currently approved as adjunctive therapy and monotherapy for partial-onset (focal) seizures. The drug enhances slow inactivation of voltage-gated sodium channels and subsequently reduces the activity of rapidly firing neurons. Eslicarbazepine acetate has few, but some, drug-drug interactions. It is a weak enzyme inducer and it inhibits cytochrome P450 2C19, but it affects a smaller assortment of enzymes than carbamazepine. Clinical studies using eslicarbazepine acetate as adjunctive treatment or monotherapy have demonstrated its efficacy in patients with refractory or newly diagnosed focal seizures. The drug is generally well tolerated, and the most common side effects include dizziness, headache, and diplopia. One of the greatest strengths of eslicarbazepine acetate is its ability to be administered only once per day. Eslicarbazepine acetate has many advantages over older anti-epileptic drugs, and it should be strongly considered when treating patients with partial-onset epilepsy.
    MeSH term(s) Animals ; Anticonvulsants/adverse effects ; Anticonvulsants/pharmacology ; Anticonvulsants/therapeutic use ; Cytochrome P-450 CYP2C19/drug effects ; Dibenzazepines/adverse effects ; Dibenzazepines/pharmacology ; Dibenzazepines/therapeutic use ; Drug Interactions ; Epilepsies, Partial/drug therapy ; Epilepsies, Partial/physiopathology ; Humans ; Voltage-Gated Sodium Channel Blockers/adverse effects ; Voltage-Gated Sodium Channel Blockers/pharmacology ; Voltage-Gated Sodium Channel Blockers/therapeutic use
    Chemical Substances Anticonvulsants ; Dibenzazepines ; Voltage-Gated Sodium Channel Blockers ; eslicarbazepine acetate (BEA68ZVB2K) ; CYP2C19 protein, human (EC 1.14.14.1) ; Cytochrome P-450 CYP2C19 (EC 1.14.14.1)
    Language English
    Publishing date 2017-09
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2020476-0
    ISSN 1179-6901 ; 1174-5886
    ISSN (online) 1179-6901
    ISSN 1174-5886
    DOI 10.1007/s40268-017-0197-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5262: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Hypothermia associated with clobazam use in adult epilepsy.

    Gauthier, Angela C / Quraishi, Imran H / Mattson, Richard H

    Epilepsy & behavior case reports

    2016  Volume 5, Page(s) 17–18

    Abstract: Clobazam, a 1,5-benzodiazepine FDA-approved in 2011, is commonly used to treat anxiety and epilepsy. It has not associated with hypothermia until very recently, in a case report involving two pediatric patients. Here, we report the first case of ... ...

    Abstract Clobazam, a 1,5-benzodiazepine FDA-approved in 2011, is commonly used to treat anxiety and epilepsy. It has not associated with hypothermia until very recently, in a case report involving two pediatric patients. Here, we report the first case of hypothermia development in an adult patient with epilepsy associated with clobazam use. A couple months after starting clobazam, the patient started developing episodes of hypothermia every several weeks, with temperatures ranging from 90 °F-95 °F. Normothermia was achieved with Bair Hugger therapy. Thyroid-stimulating hormone and cortisol levels were normal, and there was no evidence of infection in most instances. After 11 total episodes of hypothermia over a year of clobazam use, the drug was discontinued. It has now been 7 months after discontinuation, and the patient has not experienced any more episodes of hypothermia. Early recognition of the link between clobazam and hypothermia may prevent avoidable Emergency Department visits and hospitalizations.
    Language English
    Publishing date 2016-01-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2708718-9
    ISSN 2213-3232
    ISSN 2213-3232
    DOI 10.1016/j.ebcr.2016.01.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Tricyclic anticonvulsants: efficacy in clinical trials.

    Mattson, Richard H.

    Epilepsy & behavior : E&B

    2003  Volume 3, Issue 3S, Page(s) S9–S13

    Language English
    Publishing date 2003-02-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2010587-3
    ISSN 1525-5069 ; 1525-5050
    ISSN (online) 1525-5069
    ISSN 1525-5050
    DOI 10.1016/s1525-5050(02)00015-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5289: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top